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A B S T R A C T
The goals of this study were to evaluate the efﬁcacy, safety, and quality of life proﬁles of ER formulation
of valproate in patients with epilepsy. This was a prospective, multicentre, open-lable study. Patients
with a deﬁnite diagnosis of epilepsy were included and prescribed the ER formulation of valproate as
initial or add-on therapy for 6months. Efﬁcacy and safety re-evaluation procedures were performed at 1
(V1), 3 (V2), and 6 months (V3) after enrolment. A QOLIE-31 inventory was used to assess the quality of
life before and after the 6-month treatment. Nine hundred and ﬁfty-eight patients with diagnosis of
epilepsy were included in the analysis. The mean of seizure frequency at baseline was 8.56 per month.
Themedianmaintenance dose of the ER valproatewas 750 mg per day. The number of seizure attacks per
month was signiﬁcantly decreased at the last visit compared to baseline by 88.3%. Patients improved
quality of life in the ﬁelds of ‘seizureworry’ (P = 0.000), ‘overall quality of life’ (P = 0.000), ‘social function’
(P < 0.01), and ‘Question 310 (P = 0.000), but showed decreased ‘energy’ (P = 0.000). In the early phase of
treatment, the main adverse effects included drowsiness, dizziness, and anorexia. By 6 months of
treatment, weight gain, alopecia, and tremor were most frequently reported. The results of the present
study demonstrated that patients receiving ER valproate as add-on or mono-therapy for 6 months
exhibited signiﬁcantly greater median percent reductions from baseline in seizure frequency for all
seizure types, and signiﬁcantly higher responder rates and higher seizure freedom rates, with good
tolerance and improved quality of life.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Forty-one years since its clinical introduction, valproate has
become the most widely prescribed antiepileptic drug (AED)
worldwide.1 The pharmacological effects of valproate involve a
variety of mechanisms, including increased g-aminobutyric acid
(GABA)-ergic transmission, reduced release and/or effects of
excitatory amino acids, blockade of voltage-gated sodium channels,
and modulation of dopaminergic and serotonergic transmission.
Valproate is a broad spectrum AED, being effective against all
seizure types, and is available in different dosage forms for
parenteral and oral use.1 All oral formulations are almost
completely bioavailable, although they differ in dissolution
characteristics and absorption rates. In particular, extended-
release (ER) formulations are available that minimize ﬂuctuations
in serum drug concentrations during a dosing interval, and can
therefore be given once or twice daily.2 However, there are limited* Corresponding author at: Institute of Neurology, Huashan Hospital, Fudan
University, No. 12, Wulumuqi Rd. (M), Shanghai 200040, China.
Tel.: +86 21 52888158; fax: +86 21 62481930.
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1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.09.014data evaluating the efﬁcacy and tolerability of the ER formulation
of valproate, especially inmainland China. As such, we conducted a
prospective and multicentre trial with the aim of assessing the
efﬁcacy, safety proﬁles, and quality of life (QOL) issues associated
with the ER formulation of valproate in China.
2. Methods
2.1. Study design
The present studywas conducted in 21 centres acrossmainland
China. Neurologists at every study site identiﬁed eligible patients.
Clinicians were asked to identify seizures and epilepsy syndromes
by International League Against Epilepsy classiﬁcations3,4 as far as
was possible. After enrolment, patients were prescribed the ER
formulation of valproate (Deparkine Chrono) as initial or add-on
therapy. The rate of titration, initial andmaintenance dose, and any
subsequent increments or decrements were decided by the
clinician according to their everyday practice. The aim of treatment
was to control seizures with a minimum effective dose of drug,
which necessitated dose increments if further seizures took place.
Information recorded at study entry (V0) included patient
demographics, seizure onset age, seizure frequency, and AEDsvier Ltd. All rights reserved.
Table 1
Patient characteristics and epileptic details.
Gender, n (%)
Male 590 (61.6)
Female 368 (38.4)
Age at seizure onset, mean SD 14.011.58
Range At birth to 65 years
Epilepsy type, n (%)
Generalized 446 (46.6)
Focal 314 (32.8)
Uncertain 198 (20.6)
Number of concomitant AEDs, n (%)
0 671 (70.1)
1 236 (24.6)
2 51 (5.3)
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performed at 1 (V1), 3 (V2), and 6 months (V3) after enrolment.
A QOLIE-31 inventory was used to assess the QOL before and after
the 6-month treatment. The patients taking conventional valpro-
ate were directly replaced by the ER formulation at baseline. Any
other concomitant AEDs were not allowed to be adjusted or added
during the whole study period.
The studies were conducted in accordance with the Interna-
tional Conference on Harmonization Notes for Guidance on Good
Clinical Practice and the Declaration of Helsinki. The relevant study
protocol was approved by an independent Ethics Committee or
Institutional Review Board at each study centre. All patients (or a
parent or legal guardian) provided written informed consent and
all minors signed a consent form.
2.2. Study population
Patients were eligible for the study if they were 6–65 years of
age, were diagnosedwith epilepsy, experienced at least one seizure
attack in the last 3 months before baseline visit, with any seizure
type classiﬁable by the International Classiﬁcation of Seizures, and,
if female, had a negative urine or serum pregnancy test at
screening and agreed to use acceptable contraceptive methods
during the study or were incapable of bearing children. Patients
were excluded from the study for using more than two AEDs or ER
valproate, use of any investigational drug within the previous 12
weeks, chronic use of any medication that could inﬂuence seizure
control, any acute or progressive neurological or severe psychiatric
disease, and any medical condition associated with signiﬁcant
changes in body weight.
2.3. Efﬁcacy assessment
Throughout the study, each patient (or a parent or legal
guardian) recorded the date, number, and type of seizures
experienced on a daily record card which was reviewed by an
investigator at each study visit. Baseline seizure frequency was
calculated from the 3-month retrospective baseline. The efﬁcacy
endpoints included percent change in seizure frequency of any
type per month from baseline over the treatment period,
proportion of patients with 50% reduction from baseline in
seizure frequency per month (50% responder rate) during the
treatment period, and the seizure freedom rate during the
evaluation period. Only patients who completed the entire
evaluation period without experiencing any type of seizure were
considered to be seizure free, while any patient who discontinued
study medication prematurely was regarded as not seizure free.
2.4. Safety assessment
Safety was determined by assessment of adverse events,
monitoring of vital signs, and physical and neurological examina-
tions. Details recorded included intensity (mild, moderate, and
severe) and the relationship to study medication, as judged by the
investigator.
2.5. Quality of life assessment
For patients at least 18 years of age, health-related QOL was
measured in the clinic using the Quality of Life in Epilepsy
Inventory (QOLIE-31), a widely used instrument developed
especially for the evaluation of QOL in adult patients with epilepsy,
and one that has been extensively tested for validity and
reliability.5,6 QOLIE-31 consists of 31 questions divided into seven
domains: emotional well-being, social functioning, energy/fatigue,
cognitive functioning, seizure worry, medication effects, andoverall QOL. Each domain was scored by calculating the mean
score of the responses to the questions within that domain.
Question 31 is a subjective self-assessment of the subjects’ general
health condition and was not included in the seven domains.
QOLIE-31 scores at baseline and at the end of the 6-month
treatment period were computed for each sub-scale according to
the developers’ instructions. Higher scores reﬂect better QOL,
while lower ones reﬂect worse QOL.
2.6. Statistical methods
Descriptive statistics were calculated for all outcome variables,
and are expressed as mean  SD or medians and ranges as
appropriate. The percent reduction frombaseline in seizure frequency
permonthwas compared using theWilcoxon signed rank-sum test. A
50% responder, seizure freedom rates, and treatment-emergent
adverse events were summarized using descriptive statistics. Paired
T-test was used to examine the change of each item score in QOLIE-31
before and after treatment. All data were analyzed with statistical
analysis software SPSS 13.0. Differences with a P value <0.05 were
considered signiﬁcant.
3. Results
3.1. Patients sample
Nine hundred and ﬁfty-eight patients (mean age 17.6 years,
range 6–65 years) with diagnosis of epilepsy were included in the
analysis. There were 61.6% males and 38.4% females. The main
characteristics of patients can be seen in Table 1. ER valproate was
discontinued in 112 patients (11.7%) secondary to uncontrolled
seizure and adverse events.
3.2. Dosage of study drug and efﬁcacy
The median dose of ER valproate was 500 mg/d (range 125–
2000 mg/d) at V0 and was increased to 750 mg/d (range 125–
2000 mg/d) at the following visits. The median (25, 75 percentiles)
of seizure counts permonthwas signiﬁcantly decreased (P = 0.000)
at every follow-up visit when compared with the previous visit
(Table 2). The results of efﬁcacy analysis in the population of
patients treated with other AEDs and still having seizure (N = 297)
and in the population of newly diagnosed patients (N = 549) were
consistent with those in all subjects as a whole, and there was no
signiﬁcantly difference between two groups (P > 0.05). During the
6-month treatment period the median percent reduction from
baseline in seizures per month for all seizure types was 88.3%.
Overall, 90.1% of patients on ER valproate therapy had at least a 50%
seizure reduction (good responders), and 50.5% remained seizure
free (Fig. 1). According to epilepsy type, there was no difference in
Table 2
Seizure frequency per month at every visit.
Seizure freq. per month V0 (n=846) V1 (n=846) V2 (n=846) V3 (n=846) P *V0V3 P *V1V3 P * V2V3
Min 0.33 0 0 0
Max 333.0 540 160 333
Mean SD 8.5638.38 3.6920.07 1.459.21 1.0011.31
Median (25, 75 percentiles) 0.67 (1.00, 1.83) 0 (0.00, 1.00) 0 (0.00, 0.50) 0 (0.00, 0.00) 0.000 0.000 0.000
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and focal epilepsy. However, themedian dose of ER valproate at the
maintenance phase was signiﬁcant higher (P < 0.05) in patients
with focal epilepsy (1000 mg/d) than in those with generalized
epilepsy (750 mg/d), but with the same efﬁcacy.
3.3. Safety
Adverse effects that were considered to be related to study
treatment at the ﬁrst month visit occurred in 9.2% of patients, with
increased appetite, dizziness, nausea, vomiting, and declined
cognition most commonly reported. Complaints of increased body
weight, hair loss, hand tremor, and drowsiness were reported 6.7%
of patients after the 6-month treatment. Seven (0.7%) patients
were withdrawn from the study because of adverse effects.
3.4. Quality of Life
A total of 407 adult patients ﬁnished QOLIE-31 for the
evaluation of QOL at baseline and after the 6-month treatment.
A summary and comparison of the scores for each domain can be
seen in Table 3. At the end of the 6-month treatment, patient’s
experienced signiﬁcant QOL improvements on the seizure worry
(P = 0.000), overall QOL (P = 0.000), social functioning (P < 0.01),
and Question 31 (P = 0.000) domains of the QOLIE-31, while the
energy/fatigue domain was signiﬁcantly decreased (P = 0.000).
4. Discussion
Valproate is a broad spectrum AED, being effective against all
seizure types. In an early review of 41 mostly non-comparative
trials using valproate of varying duration7 efﬁcacy rates, deﬁned as
the percentage of patients showing a >75% reduction in seizure
frequency compared with baseline, indicated that valproate, used
mostly as adjunctive therapy, was effective in 61% of patients
overall, with the response usually greater in patients with
generalized seizures compared with those with partial seizures.
The UK adult EPITEG trial evaluated 300 patients with newly
diagnosed, previously untreated epilepsy, of whom approximately
one-half had partial seizures and the remaining were diagnosed as[()TD$FIG]Fig. 1. Percent change in seizure frequency of any type per month from baseline
over the treatment period.having primarily generalized tonic-clonic seizures.8 After 3 years
of follow-up, valproate and carbamazepine were found to be
equally efﬁcacious, irrespective of seizure type.
The adverse effects proﬁles of valproate have been evaluated in
clinical studies and in extensive postmarketing reports.9–11 Of the
dose-dependent adverse effects, gastrointestinal disturbances such
as nausea, vomiting, and indigestion, and more rarely diarrhoea,
abdominal cramps, and constipation, were more common at
initiation of treatment; those effects, however, are usually transient
and do not generally require discontinuation of treatment.9,12
AdverseCNS effects are less commonwithvalproate thanwith other
AEDs. In the adult EPITEG trial, 6% of patients assigned to valproate
developed tremor, compared with 2% of patients allocated to
carbamazepine.8 Less common adverse CNS effects of valproate
include headache, nystagmus, dizziness, diplopia, amblyopia,
blurred vision, incoordination, parkinsonian symptoms, and beha-
vioural or psychiatric disorders.10,13 One signiﬁcant adverse effect
during long-term treatment with valproate is the potential for
bodyweight gain14 and in the EPITEG trial the incidence of
bodyweight gain during valproate treatment was 15%.8
Valproate is a major antiepileptic drug with a wide spectrum of
activity and low toxicity. In patients on long-term therapy, plasma
valproate levels ﬂuctuate extensively within each dosing interval
due to the drug’s small distribution volume, rapid absorption, and
short half-life. To reduce the diurnal variation in plasma valproate
concentrations and to improve compliance with drug intake, ER
valproate preparations, given less frequently, are often substituted
from rapidly absorbed preparations. The ER valproate has different
pharmacokinetic proﬁles from conventional valproate, including a
delayed peak time and a reduced peak concentration.15 ER
valproate may also be useful for the prevention of valproate-
induced hepatotoxicity, the risk for whichwas enhanced with high
valproate concentrations.16 Smaller diurnal ﬂuctuations in valpro-
ate concentrations during treatment with the ER formulation were
shown to result in lowered concentrations of minor metabolites
including 4-en-valproate, the most toxic metabolite.17
The results of the present study demonstrated that patients
receiving ER valproate as initial or add-on therapy for 6 months
resulted in 88.3% reduction of seizure frequency from baseline for
all seizure types, and high responder rates and seizure freedom
rates (50.5%), while 6.7–9.2% of patients reported adverse effects
during the different phases of the study. Our results also suggested
that the dose of ER valproate used in patients with partial seizuresTable 3
QOLIE-31 evaluation before and after 6 months valproate treatment.
Domains V0 V3 T value P value
Seizure worry 50.5818.61 54.1215.84 5.66 0.000
Overall QOL 34.2411.42 38.7010.97 10.30 0.000
Emotional
well-being
42.9126.46 41.1229.38 1.64 0.157
Energy/fatigue 42.3028.42 37.7931.00 4.34 0.000
Cognitive
functioning
48.5120.80 47.4721.85 1.36 0.174
Medication effects 42.0621.60 41.9520.28 0.14 0.889
Social functioning 34.2425.33 37.6928.05 3.16 0.002
Question 31 73.6313.56 79.8712.05 15.16 0.000
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in order to gain the same efﬁcacy. These ﬁndings are generally
consistent with previous studies, although our adverse effects rate
was lower, mainly due to the favourable pharmaceutical char-
acteristics of the ER valproate.
Although remission of seizures has been found to be associated
with improvements in health-related QOL, the impact of partial
reductions in seizure frequency is more ambiguous. These
considerations highlight the importance of measuring health-
related QOL in clinical trials of antiepileptic drug therapy. The
results from the present study demonstrated improvements in
some aspects of health-related QOL as measured with the QOLIE-
31 after a 6-month treatment with ER valproate. Previous studies
have suggested that the QOL improvements occurring indepen-
dently of changes in seizure frequency may arise from factors such
as reduction in seizure severity or the positive psychotropic or
mood-stabilizing effects of antiepileptic drugs.13,16 Our data
corroborate previous observations of enhanced mood, social
interaction, and general well-being in patients with epilepsy
treated with valproate.18 Valproate has also been established as an
effective mood stabilizer in bipolar disorder in case series, open-
label studies, and double-blind, placebo-controlled trials.
A limitation of the present study was its non-randomized, non-
blind, and non-control design. To compensate for this shortcoming,
we recruited 958 patients and achieved a high level of complete-
ness of follow-up in order to increase the precision and conﬁdence
in the results.
Patients with epilepsy receiving ER valproate as add-on or
mono-therapy for 6months resulted in signiﬁcant reductions from
baseline in seizure frequency for all seizure types, and high
responder rates and seizure freedom rates. The dose of ER
valproate used in patients with partial seizures was signiﬁcantly
higher than in patientswith generalized seizure in order to gain the
same efﬁcacy. Patients with epilepsy in this study demonstrated
good tolerance and improved quality of life with 6-month
treatment of ER valproate.
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